- Home
- MRVI vs ACRS Comparison
MRVI vs ACRS Comparison
Compare MRVI & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRVI | ACRS |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 868.5M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MRVI | ACRS |
|---|---|---|
| Price | $5.76 | $6.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.13 | ★ $10.20 |
| AVG Volume (30 Days) | ★ 2.0M | 1.8M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.29 | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,743,000.00 | $1,683,000.00 |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $7.87 | $4.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.29 | $1.74 |
| 52 Week High | $7.44 | $6.52 |
Technical Indicators
Market Signals| Indicator | MRVI | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 63.42 |
| Support Level | $5.54 | $4.13 |
| Resistance Level | $6.55 | $6.52 |
| Average True Range (ATR) | 0.31 | 0.37 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 25.37 | 81.06 |
Price Performance
Historical ComparisonAbout MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.